Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

6.30USD
17 May 2019
Change (% chg)

-- (--)
Prev Close
$6.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
275,227
52-wk High
$18.25
52-wk Low
$6.23

Latest Key Developments (Source: Significant Developments)

Dynavax Reports Q1 Loss Per Share $0.62
Thursday, 9 May 2019 

May 8 (Reuters) - Dynavax Technologies Corp ::DYNAVAX ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.65 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $183.2 MILLION AT MARCH 31, 2019.  Full Article

Dynavax Technologies Expects Sales Of Heplisav-B For Quarter Ended Dec 31 To Be No Less Than $3.7 Mln
Saturday, 12 Jan 2019 

Jan 11 (Reuters) - Dynavax Technologies Corp ::DYNAVAX TECHNOLOGIES - EXPECTS SALES OF HEPLISAV-B FOR FISCAL QUARTER ENDED DEC 31, 2018 TO BE NO LESS THAN $3.7 MILLION.  Full Article

Sam's Club And Dynavax Technologies Announce Collaboration To Make Hepatitis B Vaccine
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Dynavax Technologies Corp ::SAM’S CLUB AND DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCE COLLABORATION TO MAKE HEPLISAV-B® [HEPATITIS B VACCINE (RECOMBINANT), ADJUVANTED] AVAILABLE TO SAM’S CLUB PATIENTS.DYNAVAX TECHNOLOGIES - CO, SAM'S CLUB TEAMED UP TO INTRODUCE HEPLISAV-B INTO SAM'S CLUB RETAIL PHARMACIES NATION-WIDE IN U.S..  Full Article

Dynavax Reports Q3 Loss Per Share Of $0.65
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS, PROGRESS ON HEPLISAV-B LAUNCH, AND UPDATED SD-101 DATA IN THREE PATIENT POPULATIONS.Q3 LOSS PER SHARE $0.65.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.Q3 SALES $1.5 MILLION.Q3 REVENUE VIEW $3.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Healthcor Management LP Reports 5.5 Pct Passive Stake In Dynavax Technologies Corp As Of October 1
Friday, 12 Oct 2018 

Oct 11 (Reuters) - Dynavax Technologies Corp ::HEALTHCOR MANAGEMENT LP REPORTS 5.5 PERCENT PASSIVE STAKE IN DYNAVAX TECHNOLOGIES CORP AS OF OCTOBER 1 - SEC FILING.  Full Article

Dynavax Qtrly Loss Per Share $0.45
Thursday, 8 Mar 2018 

March 8 (Reuters) - Dynavax Technologies Corp ::DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS.DYNAVAX TECHNOLOGIES CORP - QTRLY LOSS PER SHARE $0.45.  Full Article

Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Dynavax Technologies Corp :Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults.Dynavax Technologies Corp - ‍expects to commercially launch Heplisav-B in United States in Q1 of 2018​.  Full Article

Dynavax reports Q3 loss per share $0.38
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Dynavax Technologies Corp :Dynavax reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Dynavax Technologies Corp - Qtrly total revenue $53,000 versus $162,000‍​.Dynavax Technologies - ‍Cash, cash equivalents & marketable securities were $191.7 million at Sept 30, 2017 compared to $81.4 million at Dec 31, 2016​.  Full Article

Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Dynavax Technologies Corp :Dynavax initiates clinical trial in non-small cell lung cancer with a novel inhaled TLR9 Agonist in combination with Anti-PD-1 therapy.Dynavax Technologies - ‍dose escalation study is expected to enroll about 24 patients in 5 cohorts with advanced NSCLC.  Full Article

Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​
Saturday, 2 Sep 2017 

Sept 1 (Reuters) - Dynavax Technologies Corp :Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​.Dynavax Technologies - ‍proposed settlement does not involve stockholder class actions consolidated under caption in re Dynavax securities litigation​.Dynavax Technologies Corp - ‍litigation is currently pending in United States district court, northern district of California​.  Full Article